WO2001070951A3 - Mittel zur diagnose und therapie viraler erkrankungen - Google Patents

Mittel zur diagnose und therapie viraler erkrankungen Download PDF

Info

Publication number
WO2001070951A3
WO2001070951A3 PCT/DE2001/001068 DE0101068W WO0170951A3 WO 2001070951 A3 WO2001070951 A3 WO 2001070951A3 DE 0101068 W DE0101068 W DE 0101068W WO 0170951 A3 WO0170951 A3 WO 0170951A3
Authority
WO
WIPO (PCT)
Prior art keywords
diagnosis
therapy
agent
viral diseases
medicine
Prior art date
Application number
PCT/DE2001/001068
Other languages
English (en)
French (fr)
Other versions
WO2001070951A2 (de
Inventor
Hans-Dieter Royer
Karsten Juerchott
Stephan Bergmann
Original Assignee
Max Delbrueck Centrum
Royer Hans Dieter
Karsten Juerchott
Stephan Bergmann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Delbrueck Centrum, Royer Hans Dieter, Karsten Juerchott, Stephan Bergmann filed Critical Max Delbrueck Centrum
Priority to AU56117/01A priority Critical patent/AU5611701A/en
Publication of WO2001070951A2 publication Critical patent/WO2001070951A2/de
Publication of WO2001070951A3 publication Critical patent/WO2001070951A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Die Erfindung betrifft ein Mittel zur Diagnose und Therapie viraler Erkrankungen. Die erfinderische Lösung macht sich dabei spezielle Eigenschaften des zellulären Proteins YB-1 zu nutze. Anwendungsgebiete sind die Medizin und die pharmazeutische Industrie.
PCT/DE2001/001068 2000-03-23 2001-03-21 Mittel zur diagnose und therapie viraler erkrankungen WO2001070951A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU56117/01A AU5611701A (en) 2000-03-23 2001-03-21 Agent for the diagnosis and therapy of viral diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10015413A DE10015413A1 (de) 2000-03-23 2000-03-23 Mittel zur Diagnose und Therapie viraler Erkrankungen
DE10015413.1 2000-03-23

Publications (2)

Publication Number Publication Date
WO2001070951A2 WO2001070951A2 (de) 2001-09-27
WO2001070951A3 true WO2001070951A3 (de) 2002-05-02

Family

ID=7636714

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2001/001068 WO2001070951A2 (de) 2000-03-23 2001-03-21 Mittel zur diagnose und therapie viraler erkrankungen

Country Status (3)

Country Link
AU (1) AU5611701A (de)
DE (1) DE10015413A1 (de)
WO (1) WO2001070951A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002216500A1 (en) * 2000-11-28 2002-06-11 Genesis Research And Development Corporation Limited Methods for modulating apoptotic cell death
DE10150984A1 (de) * 2001-10-16 2003-04-17 Holm Per Sonne Verwendung des adenoviralen E2-late-Promotors
JP5213298B2 (ja) 2002-05-27 2013-06-19 ホルム，ペル・ゾンネ アデノウイルスおよびそれをコードしている核酸の新たな使用
PL219321B1 (pl) * 2002-10-15 2015-04-30 Per Sonne Holm Adenowirus, kodujący go kwas nukleinowy, zawierający je układ replikacyjny, wektor, komórka i organizm, ich zastosowanie oraz środek farmaceutyczny
WO2005051430A1 (de) 2003-11-14 2005-06-09 Per Sonne Holm Neue verwendung von adenoviren und dafür codierenden nukleinsäuren

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997016547A1 (en) * 1995-10-31 1997-05-09 The Board Of Regents, The University Of Texas System ADENOVIRUS-ANTISENSE K-ras EXPRESSION VECTORS AND THEIR APPLICATION IN CANCER THERAPY
WO2000003027A1 (de) * 1998-07-10 2000-01-20 Max-Delbrück-Centrum für Molekulare Medizin Verfahren zur verbesserung des gentransfers von genetischem material in säugerzellen durch die verwendung von p21 (waf-1)
US6140126A (en) * 1999-10-26 2000-10-31 Isis Pharmaceuticals Inc. Antisense modulation of Y-box binding protein 1 expression
WO2001002556A2 (de) * 1999-06-30 2001-01-11 Max-Delbrück-Centrum für Molekulare Medizin Mittel zur diagnose, prognose und therapie maligner erkrankungen

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997016547A1 (en) * 1995-10-31 1997-05-09 The Board Of Regents, The University Of Texas System ADENOVIRUS-ANTISENSE K-ras EXPRESSION VECTORS AND THEIR APPLICATION IN CANCER THERAPY
WO2000003027A1 (de) * 1998-07-10 2000-01-20 Max-Delbrück-Centrum für Molekulare Medizin Verfahren zur verbesserung des gentransfers von genetischem material in säugerzellen durch die verwendung von p21 (waf-1)
WO2001002556A2 (de) * 1999-06-30 2001-01-11 Max-Delbrück-Centrum für Molekulare Medizin Mittel zur diagnose, prognose und therapie maligner erkrankungen
US6140126A (en) * 1999-10-26 2000-10-31 Isis Pharmaceuticals Inc. Antisense modulation of Y-box binding protein 1 expression

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ANSARI SAMEER A ET AL: "Interaction of YB-1 with human immunodeficiency virus type 1 Tat and TAR RNA modulates viral promoter activity.", JOURNAL OF GENERAL VIROLOGY, vol. 80, no. 10, October 1999 (1999-10-01), pages 2629 - 2638, XP002177053, ISSN: 0022-1317 *
CHENG, S. ET AL.: "The tumor metastasis suppressor, NDPK-beta, inhibits gelatinase A gene transcription by interference with transactivator YB-1", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. 10, no. PROGRAM AND ABSTR. ISSUE, September 1999 (1999-09-01), pages 569A, XP000978754, ISSN: 1046-6673 *
KOIKE, K. ET AL.: "Nuclear translocation of the Y-box binding protein by ultraviolet irradiation", FEBS LETTERS, vol. 417, no. 3, 17 November 1997 (1997-11-17), pages 390 - 394, XP002177054, ISSN: 0014-5793 *
OHGA, T. ET AL.: "Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA damaging agents cisplatin, mitomycin C, and ultraviolet light", CANCER RESEARCH, vol. 56, no. 18, 1996, pages 4224 - 4228, XP002157301, ISSN: 0008-5472 *
SAFAK MAHMUT ET AL: "Physical and functional interaction between the Y-box binding protein YB-1 and human polyomavirus JC virus large T antigen.", JOURNAL OF VIROLOGY, vol. 73, no. 12, December 1999 (1999-12-01), pages 10146 - 10157, XP002177057, ISSN: 0022-538X *
TANGE THOMAS OSTERGAARD ET AL: "In vitro interaction between human immunodeficiency virus type 1 Rev protein and splicing factor ASF/SF2-associated protein, p32.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 17, 1996, pages 10066 - 10072, XP002177056, ISSN: 0021-9258 *
WANG YILONG ET AL: "P32/TAP, a cellular protein that interacts with EBNA-1 of Epstein-Barr virus.", VIROLOGY, vol. 236, no. 1, 1997, pages 18 - 29, XP002177055, ISSN: 0042-6822 *

Also Published As

Publication number Publication date
AU5611701A (en) 2001-10-03
DE10015413A1 (de) 2001-09-27
WO2001070951A2 (de) 2001-09-27

Similar Documents

Publication Publication Date Title
IL157656A (en) Metalloproteinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for the treatment of diseases mediated by metalloproteinase enzymes
IL195723A (en) Use of p53 inhibitors for the preparation of medicament
DK1289517T3 (da) Farmaceutiske sammensætninger indeholdende cannabidiolderivater
NO20015584L (no) Langtidsvarende insulintropiske peptider og konjugater samt anvendelse for fremstilling av medikamenter for behandling
HK1070080A1 (en) Ganglioside-associated recombinant antibodies and the use thereof in the preparation of medicament for the diagnosis and treatment of tumors
WO2003099771A3 (en) Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
HUP0102033A2 (hu) PEG IFN-alfa és ribavirin felhasználása krónikus hepatitis C kezelésére
PT1079806E (pt) Preparacoes para a aplicacao de anti-inflamatorios, especialmente, agentes anti-septicos e/ou agentes de promocao da cura de feridas, no tracto respiratorio superior e/ou no ouvido
WO2002091997A3 (en) Oncolytic virus therapy
SE9704833D0 (sv) New formulation
AU2002341558A1 (en) Compositions and methods useful for non-invasive delivery of therapeutic molecules to the bloodstream
WO2002069945A3 (de) Neue arzneimittelkompositionen auf der basis von anticholinergika und pde-iv-inhibitoren
HK1068606A1 (en) Novel aminobenzoephenones
EE200400028A (et) Ravimpreparaat, selle valmistamise meetod ja selle kasutamine meditsiinis
DE60119976D1 (en) Thixotropes nasenspray
WO2001070951A3 (de) Mittel zur diagnose und therapie viraler erkrankungen
EP1180017B8 (de) Formulierungen mit povidon-iod zur behandlung von wunden
WO2002000208A3 (de) Kombinationspräparate von 3-n-formylhydroxylaminopropylphosphonsäurederivaten oder 3-n-acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen
WO2001028535A3 (en) Pharmaceutical formulations comprising a combination of s-salmeterol and fluticasone propionate
EP1583545A4 (de) Pharmazeutische zusammensetzung für die verbesserte verabreichung von peptiden von hiv gp41 und ihre therapeutische verwendung
AU2002340728A1 (en) Tt virus sequences in human tumoral tissue, agent for the detection thereof and tumoral therapy
AU2003294834A1 (en) Anthranilic acid amide derivatives and their pharmaceutical use
AU2003258550A1 (en) Splicing-variant of the human p53 protein and use thereof in the production of pharmaceutical preparations for treating tumoural diseases
UA37445A (uk) Протизапальний засіб
AU2002356673B2 (en) Medicament for the treatment of viral skin and tumor diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP